Regencell Bioscience Holdings Limited focuses on the research, development, and commercialization of Traditional Chinese Medicine (TCM) in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, TCM brain theory, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.…
Regencell Bioscience Holdings (RGC) Stock Looks Rich After A Very Large Run
Regencell Bioscience Holdings (NASDAQ: RGC) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 10 employees.
The shares were at 4.180 USD on 20 November 2026, down 68.5% over 52 weeks. Its 52-week range is 4.120 USD to 69.00 USD: the price is 93.9% below the high and 1.5% above the low.
Its market capitalisation is 2.07B USD.
Regencell Bioscience Holdings reports return on equity of -87.7% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 13.90M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 6 May 2027.